Repligen Completes Acquisition of BioLife Solutions

Repligen describes the acquired consumables business as high-margin with recurring revenue.

Rhea-AI Summary

Repligen (NASDAQ: RGEN) has completed its previously announced acquisition of BioLife Solutions, adding cell processing tools and services for cell therapies.

BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash paid instead of fractional shares. BioLife's biopreservation media portfolio, led by CryoStor, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.

Repligen expects the combination to broaden its cell therapy presence and connect BioLife's customer relationships with its global commercial reach, including Asia Pacific. The company intends to provide details on the transaction's expected impact on its 2026 financial outlook during its upcoming third-quarter earnings call.

3 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointBioLife acquisition completed, adding cell processing tools and services to Repligen's business.
• Minor pointAcquired consumables business brings high margins and recurring revenue, in Repligen's assessment.
• Minor point. Forward-looking: it has not happened yet and may not happen.Combined commercial team is expected by Repligen to connect BioLife customer relationships with broader global reach.

Negative

• Moderate point$11.25 cash per BioLife share formed the cash cost of the acquisition.
• Minor point0.1442 Repligen shares per BioLife share issued as consideration dilute existing Repligen holders.

News Explained

The completed stock consideration gives BioLife holders an ownership stake in Repligen; issuing additional shares increases the share count and reduces existing holders’ percentage ownership, absent offsetting changes.

Key Figures

Cash consideration: $11.25 per BioLife share Stock consideration: 0.1442 Repligen shares per BioLife share Commercially approved therapies supported: 18 therapies

Cash consideration

$11.25 per BioLife share

Cash paid to BioLife stockholders

Stock consideration

0.1442 Repligen shares per BioLife share

Repligen common stock issued to BioLife stockholders

Commercially approved therapies supported

18 therapies

BioLife's biopreservation media portfolio

Previous Acquisition Reports

1 past event · Latest: Jul 22

Same Type 1 event

1. Jul 22

   Acquisition agreement

   24h Move

   +2.3%

   July agreement disclosed cash-and-stock consideration and targeted Q4 closing; this release confirms completion.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biopreservation media, cdmos, fractional shares, cash in lieu

4 terms

biopreservation media technical

"BioLife’s differentiated biopreservation media portfolio, led by CryoStor®"

Biopreservation media are specially formulated liquids used to keep cells, tissues or biological samples alive and stable during storage and transport, like a refrigerated packing solution that prevents damage and decay. For investors, the quality of these media matters because they influence product shelf life, success of lab tests, regulatory acceptance, and logistics costs for therapies and diagnostics—factors that affect revenue, margins and market adoption.

cdmos technical

"contract development and manufacturing organizations (CDMOs) worldwide"

Contract Development and Manufacturing Organizations (CDMOs) are independent companies that help drug and biologic developers by designing, testing, scaling up and producing medicines on a contract basis — think of them as a hired factory and research partner that turns a medical idea into a manufacturable product. They matter to investors because they provide steady, service-based revenue, spread development and production risk for drug makers, and their capacity, quality and pricing can directly affect the speed and cost of getting medicines to market.

fractional shares financial

"cash in lieu of any fractional shares of Repligen common stock"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

View in glossary

cash in lieu financial

"with cash in lieu of any fractional shares"

Cash in lieu is a cash payment made instead of issuing a fractional share when a corporate action (such as a stock dividend, spin-off, split, merger, or conversion) would otherwise entitle a holder to less than one full share. Transfer agents or brokers aggregate fractional entitlements and pay each holder a monetary amount equal to the fractional portion multiplied by a price determined for the transaction (commonly a closing price, average price over a set period, or a contract-specified price); the exact calculation and any rounding or fees are set by the issuer, transfer agent or the transaction documents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Has Repligen completed its acquisition of BioLife Solutions?

Repligen has completed the acquisition of BioLife Solutions. The acquired business develops and supplies cell processing tools and services for the cell and gene therapy market.

What did BioLife stockholders receive in the Repligen acquisition?

BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock. Cash was paid instead of any fractional Repligen shares.